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Abstract
Autophagy is an important catabolic process in which cells digest and recycle their own cytoplasmic contents for
maintaining cellular homeostasis. Interestingly, autophagy could play both pro-death and pro-survival roles in
influencing the development of cancer via various signal pathways. As radiotherapy is one of the main treatment
modalities for cancer, we reviewed the effect of autophagy modulations on radiosensitivity and radiotherapy
efficacy in various cancer types. The future development of autophagy modifications for improving radiotherapy
efficacy and cancer prognosis will also be discussed.
Keyword: Autophagy, Radiotherapy, Signalling pathway, Radiotherapy efficacy, Radiosensitivity, Cancer Cell lines
Background
Autophagy, a word derived from Greek “auto” (self ) and
“phagos” (to eat), is a catabolic process in which the cells
digest and recycle their own cytoplasmic contents. This
critical process is evolutionarily conserved from unicel-
lular organisms to humans and continuously occurs at
basal level to ensure healthy cellular homeostasis by
eliminating waste and long-lived or damaged cellular
constituents. There are three types of autophagy, includ-
ing macroautophagy, microautophagy and chaperone-
mediated autophagy [1]. Macroautophagy (hereby
referred to as autophagy) is the major autophagy path-
way to be discussed in this review. The process is con-
trolled by 36 highly conserved genes which are known
as AuTophaGy genes (ATGs) and starts with double-
membrane vesicles called autophagosomes, which would
fuse with lysosomes to degrade cytoplasmic contents
back to their original constituents by hydrolytic enzymes
(Fig. 1). Different stimuli including aggregated or mis-
folded proteins, stress, pathogens, cytokines, starvation
and protein synthesis inhibition might induce autophagy.
Apart from maintaining cellular homeostasis, autophagy
(or autophagy defects), may lead to several pathological
conditions, including cancer [2–4].
Relation of autophagy to cancer
Autophagy plays an important role in cancer because of
its tumour suppressing and tumour protecting function.
For tumour suppressing function at the initiation stage,
ATG Beclin-1 (Fig. 1) was identified as a tumour sup-
pressor gene as it is mono-allelically deleted in many
cases including ovarian cancers (75%), breast cancers
(50–70%) and prostate cancers (40%) [5]. Also, Beclin-1
is allelically deleted and weakly expressed in most hu-
man breast carcinoma cell lines while the normal epithe-
lium cells demonstrated a much higher expression [6].
In addition, overexpression of Beclin-1 in human breast
carcinoma cell line MCF-7 cells could reduce tumouri-
genesis by inhibiting cell proliferation in a xenograft
model [2]. Thus, low expression of Beclin-1 could favour
the development of cancer. For colorectal and gastric
cancers, associations were found with the down-
regulation of Bif-1 and Atg2B, Atg5, Atg9B and Atg12
mutations, which led to inhibition of programmed cell
death in colon cancer (Fig. 1). Also, mutation of exon 8
of UV radiation resistance-associated gene (UVRAG) re-
duced autophagy and promoted these cancer types [2, 4].
Taken together, there is broad evidence that autophagy
and ATG type of proteins have a tumour suppressive role
and down-regulation of the latter can promote tumouri-
genesis in early stage tumours.
Apart from direct suppression of tumourigenesis, au-
tophagy could also induce cellular senescence, which is a
state of stable cell cycle arrest that protect the cells
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against a variety of cellular insults. It is a delayed stress
response with multiple effector mechanisms including
oncogene-induced senescence. Oncogene initially in-
duces a highly proliferative state in cells. However, sen-
escence will gradually replace the mitotic burst state and
this illustrates its tumour suppressing role. A past study
has demonstrated that the autophagy marker
microtubule-associated protein 1 light chain 3β
(MAP1LC3) was up-regulated in Ras oncogene-induced
senescence and resulted in the accumulation of autopha-
gosomes in these cells [7]. The lack of Atg5 or Atg7
could also diminish oncogene-induced senescence and
delay the production of senescence-associated cytokine
[4]. These pieces of evidence support the notion that
senescence may be promoted by autophagy and basal
autophagy is important in restricting proliferation during
oncogenic stress. In addition, combining autophagy acti-
vation by rapamycin and irradiation could initiate pre-
mature senescence in both in vitro and in vivo models
of radiation-resistant glioblastoma and parotid carcin-
oma cells. In the in vitro model, irradiation increases au-
tophagic flux for 72 h and the addition of rapamycin
further intensified the effect. During this period, the
senescence-associated β-galactosidase activity also
showed that premature senescence has been initiated,
caused by the inhibition of mechanistic target of rapa-
mycin (mTOR) pathway. Similar results have also been
obtained in tumour xenografts [8].
In a converse way to the pro-death roles of autophagy
in cancer cells, autophagy also has pro-survival func-
tions. As vascularisation is poor in fast growing and late
stage tumours with populations of tumour cells beyond
oxygen diffuse distance or supported by malformed ves-
sels, autophagy is stimulated by an inadequate oxygen
and nutrient supply and inefficient waste removal. In
addition, the withdrawal of growth factors, accumulation
of oxidised and aggregated proteins and intracellular cal-
cium, production of reactive oxygen species (ROS) and
ammonia might also stimulate autophagy [2]. In these
stressful conditions, autophagy helps tumour cells to
maintain homeostasis and becomes a main determent of
successful therapy, including radiotherapy. However, ex-
cessive stress could also lead to cell death due to the de-
generation of the majority of cellular contents [9]. In
this review, the role of autophagy in influencing radio-
sensitivity of various cancer types will be discussed in
detail.
Relation of autophagy with ionising radiation
Numerous pharmaceutical studies have tried to promote
or inhibit autophagy through various pathways in order
to improve the outcome of cancer treatment. However,
the relationship between radiotherapy and autophagy
has not been studied in depth. As apoptosis only ac-
counts for 20% or less of radiation-induced cell death,
other cell death pathways including autophagy should
also be studied [10]. It is known that radiotherapy treat-
ment is one of the stresses that induces autophagy in
both cancer and normal cells [11]. An in vitro study in-
volving the irradiation of glioblastoma multiforme
(GBM) cells has shown that cells have died through au-
tophagy without the involvement of apoptosis [12]. Al-
though the specific mechanism that links between
radiation and autophagy has not been well established,
Fig. 1 Title: An overview of the central autophagy mechanism. The ULK and Beclin 1 protein complexes initiate phagophore formation. Atg5/12/
16 and LC3-II are responsible for expansion to autophagosome. Fusion of autophagosome and lysosome produces autolysosome as the final
process. Legend: Green arrows represent activating processes for autophagy stimulation and the red arrow represents a repressing process for
autophagy inhibition
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there were some studies that linked mTOR pathway and
endoplasmic reticulum (ER) stress to radiation-induced
cell death. For the mTOR pathway, radiation could cause
decreased phosphorylation of the autophosphorylation
site of p-mTOR (decreased p-mTOR/mTOR ratio) in an
in vitro study of MCF-7 breast cancer cell line [13].
While for ER stress, radiation could cause increased pro-
tein kinase-like endoplasmic reticulum kinase (PERK)/
eukaryotic initiation factor 2α (eIF2α) expression in
caspase-3/7-deficient cells or ER stressor tunicamycin
(TM) treated MCF-7 cells, and increased endoplasmic
reticulum protein 29 (ERp29) expression in intestinal
epithelial cells IEC-6 [14, 15]. The radiation-induced ER
stress protein expression is linked to protein folding and
unfolded protein response (UPR) and thus, radiation-
induced autophagy [10].
Ionising radiation-related autophagy signalling
pathways
PI3K-Akt-mTOR
The phosphatidylinositol-3-kinase (PI3K)-protein kin-
ase B (Akt)-mTOR pathway (Fig. 2) is one of the
most important autophagy signalling pathways in can-
cer growth and progression [2]. Hormones, growth
factors, tumour suppressors and oncogenes can acti-
vate class-I PI3K to catalyse phosphatidylinositol-3
phosphate production, causing activation and phos-
phorylation of a serine/threonine kinase PI3K-Akt.
Akt will then activate mTOR through ribosomal
protein S6 kinase (RPS6KB1) and by phosphorylating
and inhibiting tuberous sclerosis complex (TSC),
which originally inhibits mTOR [2]. mTOR is a part
of two multiprotein complexes, namely mechanistic
target of rapamycin complex 1 and 2 (mTORC1 and
mTORC2). In addition, Ras homolog enriched in
brain (Rheb-GTP) can act as a substrate for TSC2
and activate mTORC1 by GTPase. Rheb has found to
be expressed in prostate cancer and could promote
tumourigenesis with PTEN haplo-insufficiency [16].
mTORC1 regulates autophagy by controlling protein
synthesis through regulation of transcriptional regula-
tors 4E binding protein 1 (4E-BP1) and p70 ribosomal
protein S6 kinase (p70S6K) while mTORC2 is inde-
pendent to nutrient availability and phosphorylates
Akt and inhibits autophagy [4, 16]. mTORC1 activa-
tion would also inhibit autophagy by inhibiting Unc-
51-like kinase 1 (ULK1) and the inhibition of
mTORC1 could trigger autophagy and be used in
cancer therapy. According to the name of mTOR, its tar-
get is rapamycin, which has been utilized for cancer ther-
apy, such as its derivative RAD001 which is used in the
treatment of renal cancer. Other mTOR inhibitors include
pp242, Torin 1 and 2, temsirolimus, could be used to acti-
vate autophagy [2]. Apart from mTOR inhibitors, the
negative regulator of the PI3K/Akt pathway AHRI, dual
PI3K/mTOR inhibitors PI-103 and NVP-BEZ235, Akt in-
hibitors and the tumour suppressor gene PTEN may also
be used to promote cell death in tumour cells [2, 4].
Fig. 2 Title: In PI3K-Akt-mTOR signaling pathway, PI3K inhibits autophagy via activation of Akt. Akt promotes mTORC1 both directly and indirectly
through inhibiting TSC complexes. mTORC1 directly inhibits autophagy as the final step. Legend: Green arrows represent activating or repressing
processes for autophagy stimulation and red arrows represent activating or repressing processes for autophagy inhibition
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UPR
Apart from the PI3K-Akt-mTOR pathway, UPR (Fig. 3)
might also regulate autophagy to relieve stress and re-
establish cell homeostasis. Different pathological condi-
tions from cancer and various cancer treatments, such
as radiotherapy, could cause an accumulation of mis-
folded proteins in the ER and result in ER stress. There-
fore, UPR may be up-regulated by some cancer types for
improving tumour growth and therapy resistance. The
pathway of UPR includes three parallel operating com-
ponents, including PERK, activating transcription factor
6 (ATF6) and inositol requiring enzyme-1 (IRE1). These
three components are affected by glucose-regulated pro-
tein 78 (GRP78), which is an ER chaperone and deacti-
vates the three components by binding them in a
normal condition. When there is an accumulation of un-
folded proteins in the ER, GRP78 would bind to the un-
folded proteins instead of the three components and
thus activate the three components. Among the three
components, the PERK-arm has been linked to
radiation-induced autophagy for improving tumour cell
survival under radiotherapy [14]. The PERK-arm con-
tributes to hypoxia tolerance and phosphorylates elF2α,
which leads to the general stop of protein synthesis in
order to lessen the protein load in the ER. On the con-
trary, some cells may have a non-phosphorylatable eIF2α
mutation and increase hypoxia sensitivity. Although
transcription has been generally stopped, some factors
are up-regulated such as NF-E2-related factor 2 (NRF2),
nuclear factor κB (NF-κB) and activating transcription
factor 4 (ATF4). NRF2 could induce transcription of
cytoprotective genes under stress and provide resistance
to anticancer therapies and aggressive tendency in cell
proliferation with NRF2 accumulation leading to poor
prognosis in non-small-cell lung cancer [17]. NF-κB acti-
vation causes the production of anti-apoptotic proteins
[18], while ATF4 allows the restoration of normal ER
function through the induction of C/EBP homologous
protein (CHOP), growth arrest and DNA damage-
inducible protein 34 (GADD34) and lysosome-associated
membrane protein 3 (LAMP3). CHOP is the pro-
apoptotic component of the UPR and mediates cell
death when the cell adaptation fails to withstand the
ER stress whereas GADD34 is able to dephosphory-
late eIF2α as a negative feedback loop. LAMP3 in-
duces fusion of autophagosome and lysosome, which
increases resistance to cancer therapies and promotes
metastasis [2].
Mitogen-activated protein kinases (MAPK)
MAPK (Fig. 3) regulate cell proliferation and survival by
autophagy, which includes c-Jun N-terminal kinase
(JNK) and extracellular signal-regulated kinase (ERK).
JNK is activated by various stresses and it mediates au-
tophagy both directly and indirectly. Directly, JNK can
promote cell death in cancer cells by inducing p53 and
Atg5. Indirectly, JNK inhibits the association of Bcl-2
with Beclin-1 and upregulates Beclin-1 expression by c-
Jun phosphorylation. JNK could be inhibited by
SP600125 which in turn inhibits Beclin-1 expression and
autophagy [2]. Whereas ERK is activated by active cell
proliferation signals and significantly overexpressed in
cancer cells. ERK is a component of the proto-oncogene
c-RAF (Raf)- mitogen-activated protein kinase kinase
(MEK)-ERK pathway of the Ras small GTPase. The Ras
family has frequent mutations in cancer cells, which
Fig. 3 Title: For UPR signaling pathway, PERK and IRE1 activate autophagy through endoplasmatic reticulum stress. PERK promotes ATF4 and
CHOP, which results in the promotion of ATG gene expression. IRE1 activates JNK, which belongs to the MAPK pathway. JNK promotes
autophagy through the inhibition of Bcl-2 and activation of Beclin-1. Legend: Green arrows represent activating or repressing processes
for autophagy stimulation and the red arrow represent a repressing process for autophagy inhibition
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creates a high level of basal autophagy in cancer cells
even if there is a good supply of nutrients. Ras is an up-
regulator of Raf-MEK-ERK pathway by binding and
activating Raf. Raf then activates MEK and MEK can ac-
tivate and phosphorylate ERK1 (p44) and ERK2 (p42),
which can promote autophagy without other stimuli.
Apart from promoting Raf-MEK-ERK pathway, Ras can
also activate the PI3K pathway for repressing autophagy
and thus Ras has a regulatory role in autophagy [4].
Effect of autophagy modulation on radiotherapy
efficacy in different cancer types
Since autophagy can sustainably affect cell proliferation
and survival, various trials have been conducted to
modulate autophagy for improving the outcome of can-
cer treatment in combination with currently used treat-
ment modalities such as radiotherapy in different cancer
types. Table 1 summarises the effects of autophagy
modification in improving radiosensitivity or radiother-
apy efficacy through various autophagy signalling path-
ways in different cancer types.
Glioblastoma
Glioblastoma is an aggressive brain cancer with a poor
prognosis despite the use of a multimodality treatment
such as radiotherapy combined with Temozolomide
(TMZ) [19]. Past studies have been performed to investi-
gate the possible adjuvant therapy by controlling cell death.
In an in vitro study, the difference between high radiosen-
sitivity glioblastoma cell line T98G and low radiosensitivity
cell line U373MG in autophagy has been studied and it
was found that autophagy activation after radiotherapy was
more prominent in T98G than U373MG from the assess-
ment of Beclin-1 and Atg5 expressions. After adding the
mTOR inhibitor rapamycin in the two cell lines, autophagy
inductions were observed and radiosensitivities were en-
hanced in both cell lines [19]. A similar result was obtained
by Wang et al. (2013) [20], who used a dual PI3K/mTOR
inhibitor NVP-BEZ235 in glioblastoma cell line SU2 and
demonstrated that NVP-BEZ235 could radiosensitise SU2
by activating autophagy. While another study focussed on
UPR and hypoxia, the results showed that hypoxia was able
to stimulate autophagy in U373MG cells from increased
expression of MAP1LC3B and Atg5 [21]. MAP1L3B is ac-
tivated by transferring from cytosolic MAP1LC3B-I to lapi-
dated membrane-bound form of MAP1LC3B-II, and this is
strictly dependent on Atg5. Also, these two autophagy
genes are regulated by the PERK-arm of UPR and
PERK is able to activate elF2α, which in turn activates
ATF4 and CHOP. Further analyses in the study
showed that ATF4 and CHOP activate MAP1LC3B
and Atg5 respectively. The adding of the lysosomo-
trophic agent chloroquine (CQ) blocked the final step
of autophagy, causing further accumulation of
MAP1LC3B apart from hypoxic stress and this
addition of CQ has been found to increase the radio-
sensitivity of xenograft from U373MG cells [21]. The
positive results from these studies may be considered
for the development of new treatment strategies and
improve the prognosis of this deadly cancer type.
Table 1 Effects of autophagy modifications on improving radiosensitivity or radiotherapy efficacy
Cancer type Cell line Autophagy agent (Induction
(+)/ Inhibition (−))
Autophagy pathway affected Animal study
(Yes (+)/ No (−))
Reference
Glioblastoma T98G + U373MG Rapamycin (+) PI3K-Akt-mTOR (mTOR inhibitor) - Palumbo et al. [19]
SU2 NVP-BEZ235 (+) PI3K-Akt-mTOR (PI3K/mTOR inhibitor) - Wang et al. [20]
U373MG Chloroquine (−) UPR (PERK) + Rouschop et al. [21]
Oral cancer OC3 + SAS Rapamycin (+) PI3K-Akt-mTOR (mTOR inhibitor) - Wu et al. [24]
Lung cancer H460 RAD001 (+) PI3K-Akt-mTOR (mTOR inhibitor) + Kim et al. [25]
H460 Rapamycin (+) PI3K-Akt-mTOR (mTOR inhibitor) + Kim et al. [26]
CDDP-Resistant H460 NVP-BEZ235 (+) PI3K-Akt-mTOR (PI3K/mTOR inhibitor) - Kim et al. [27]
Breast
cancer
MDA-MB-23 +MCF-7 RAD001 (+) PI3K-Akt-mTOR (mTOR inhibitor) - Albert et al. [29]
MCF-7 Rapamycin (+) PI3K-Akt-mTOR (mTOR inhibitor) - Paglin et al. [13]
Oesophageal
cancer
EC109 Tunicamycin (+) PI3K-Akt-mTOR (ER stressor) + Pang et al. [30]
Pancreatic
cancer
MIA PaCa-2 + PANC-1 MG132 (+) MAPK (JNK) (Proteasome inhibitor/
ER stressor)
+ Chiu et al. [32]
Colorectal
cancer
HCT-116 BCG/CWS (+) MAPK (JNK/ERK) + Yuk et al. [33]
HCT-116 + HT-29 Chloroquine (−) UPR (PERK) + Rouschop et al. [21]
Prostate
cancer
Biopsy specimens MG132 (+) MAPK (JNK) (Proteasome inhibitor/
ER stressor)
- Koukourakis et al. [34]
DU145 + PC3 RAD001 (+) PI3K-Akt-mTOR (mTOR inhibitor) - Cao et al. [35]
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Oral cancer
Oral cancer comprises about 85% of all head and neck
cancers and the 5-year survival has shown little improve-
ment for decades [22, 23]. The main treatment modal-
ities include surgery and radiotherapy and squamous cell
carcinoma is the most common neoplasia of oral cancer.
Thus, Wu et al. (2014) [24] investigated the relationship
between radiation and autophagy in human oral squa-
mous cell carcinoma cell lines OC3 (Derived from betel
quid chewing patients) and SAS (Derived from non-
betel quid chewing patients) in an in vitro experiment.
The results showed irradiation was able to induce au-
tophagy in both OC3 and SAS cells with OC3 having a
greater increase in the rate of autophagy. Further ana-
lysis showed the involvement of the mTOR pathway in
both cell lines but the upstream autophagy pathways in-
volved were different for the two cell lines. Autophagic
degradation occurred in irradiated OC3 cells while
autophagosome accumulation occurred in irradiatied
SAS cells. Therefore, irradiation-mediated cell death oc-
curred only in OC3 cells and irradiation did not reduce
cell viability in SAS cells. Treatment of rapamycin (au-
tophagy inducer) in combination with irradiation in
OC3 cells resulted in a further reduction in cell viability,
suggesting the synergistic effects of irradiation and au-
tophagy incuction in OC3 cells [24]. The difference in
irradiation-induced growth inhibition between the two
cell lines requires further investigation in order to de-
cipher the actual mechanisms of irradiation-mediated
autophagic degradation.
Lung cancer
As lung cancer is one of the most common cancers and
current treatment modalities of radiotherapy and
chemotherapy are only able to yield moderate survival
benefits with significant side-effects. Research has been
conducted on autophagy to improve the treatment out-
come, especially for advanced non-small cell lung cancer
(NSCLC) [25]. The main focus is mTOR inhibition com-
bined with apoptosis induction or inhibition. In a study
conducted by Kim et al. (2008) [25], mTOR inhibitor
(autophagy inducer) RAD001 and caspase-3 inhibitor
(apoptosis inhibitor) Z-DEVD were injected into H460
lung cancer xenografts in vivo. The results showed that
the combined use of RAD001 and Z-DEVD followed by
radiotherapy treatment caused the greatest delay in
tumour growth, for 9 days, when compared with radio-
therapy alone. Also, there were the greatest reductions
in cellular proliferation by Ki67 staining and angiogen-
esis by von Willebrand Factor (vWF) staining in the tri-
modality treatment group. Moreover, in a further
research study by Kim et al. (2009) [26], the combined
use of mTOR inhibitor (rapamycin) and apoptosis in-
ducer (Bcl-2 inhibitor) ABT-737 with radiotherapy led to
further tumour control in the H460 lung cancer mouse
xenograft model. Their results include increase in
tumour growth delay by 7 days, decrease in cell prolifer-
ation by 77% and vascular density by 67.5% when com-
pared with radiotherapy alone [26]. Another study
demonstrated the enhancement of radiosensivity by
using NVP-BEZ235 to block the PI3K/mTOR pathway
in cisplatin-resistant NSCLC tumour cells both in vitro
(reduced survival fraction after irradiation) and in vivo
(increase in tumour growth delay) settings [27]. These
research studies show the importance of autophagy in
the control of lung cancer through autophagy mechan-
ism. Combined with irradiation and autophagy promo-
tion, the first two studies demostrated the most
prominent cell death effect during apoptosis inhibition
and promotion respectively [25, 26]. This conflicting re-
sults warrant further research in respect of the inter-
action between autophagy and apoptosis, particularly for
the quantification of both autophagy and apoptosis
levels.
Breast cancer
The relationship between irradiation and autophagy was
also studied in breast cancer cells. In an in vitro study,
radiotherapy was found to induce autophagy in the
MDA-MB-23 breast cancer cell line through PI3K-Akt-
mTOR pathway, in which the rate of autophagy was in-
creased to improve tumour cell survival [28]. Another
study also confirmed the role of autophagy in MCF-7
and MDA-MB-231 breast cancer cell lines. The addition
of mTOR inhibitor RAD001 promotes autophagy and
increases the radiosensitivity of tumour cells in an in
vitro model [29]. The action of mTOR inhibitor in
radiotherapy treatment of breast cancer was further
studied by Paglin et al. (2005) [13]. In addition to in-
creased cell death, the combination of autophagy induc-
tion and radiotherapy showed an increase in mitochondria
hyperpolarization. The results were confirmed by the
decrease in mitochondrial membrane potential, signalling
mitochondria dysfunction and increase in phosphorylation
of p53 at Ser15, which is a regulator of apoptosis and
tumour suppressor mutated in 50% of all tumours [13].
These results showed that autophagy might help breast
tumour cells to survive under treatment stress and the
suitable control of autophagy might improve the treat-
ment outcome of radiotherapy.
Oesophageal cancer
Oesophageal cancer is also a cancer with a poor progno-
sis which is treated by radiotherapy combined with other
treatments. However, different tumours of the same
grade have differential radiosensitivities and this limits
the effectiveness of radiotherapy. Thus, a recent study
investigated ER stress and autophagy in oesophageal
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cancer. An ER stress inducer, TM was applied to the
oesophageal cancer cell line EC109 followed by irradi-
ation [30]. An increase in acute cell death and decrease
in colony survival were observed, showing the radiosen-
sitising property of TM. Also, enhanced apoptosis result-
ing from an increase in cleaved caspase-3, and increased
autophagy from increased LC3-I/LC3-II ratio in Western
blotting analysis were noted. Moreover, mTORC1 was
significantly up-regulated and PI3K and phosphorylated
Akt reduced after TM treatment, suggesting the involve-
ment of PI3K-Akt-mTOR pathway in radiosensitising
EC109 cells. However, the inhibition of autophagy by
Beclin-1 knockdown showed an increase in apoptosis
and decrease in cell viability, thus autophagy could also
have cytoprotective roles in stressed tumour cells [30].
The experiment was repeated using a mouse model and
the observation of delay in tumour growth and involve-
ment of PI3K-Akt-mTOR pathway validated the in vitro
findings. The findings are controversial as autophagy
causes both cell death or provides cytoprotection, which
could be due to the influence of tumour stages on the
character of autophagy as autophagy usually acts as a
tumour suppressor in the early stages and provides
tumour protective functions in developed tumours [31].
Pancreatic cancer
Pancreatic cancer also has a poor prognosis under
current combined treatment. Chiu et al. (2015) [32] in-
vestigated the action of a proteasome inhibitor MG132
and radiotherapy in two pancreatic cancer cell lines
MIA PaCa-2 and PANC-1 in vitro and in vivo. Results
showed that the combined modalities increased ER
stress, increased IRE1α protein level, promoted autoph-
agy induction, increased detection of early apoptosis and
cell death and increased MAP1LC3 level. The results
were cross validated by adding the autophagy inhibitor
3-methyladenine (3-MA). The experiment was also re-
peated with an animal model and it was found that the
combined treatment was able to increase tumour growth
delay when compared with the MG132 or radiotherapy
alone group [32]. This study also showed the down-
regulation of TRAF6 though the combination of MG132
and irradiation. As TRAF6 represents a potential target
for tumourigenesis in pancreatic cancer, further investi-
gation is suggested for employing autophagy modulation
in improving prognosis.
Colorectal cancer
Colorectal cancer is the third most common cancer in
men and the second most common cancer in women
worldwide with surgery as the primary treatment.
Whereas radiotherapy is widely used for rectal cancer as
preoperative or postoperative adjuvant therapy [22]. Ef-
forts have been made to investigate the modification of
autophagy in improving treatment effectiveness. Yuk
et al. (2010) [33] used Mycobacterium bovis Bacillus
Calmette-Guerin (BCG/CWS) as an inducer of cell
death in both in vitro and in vivo models. It is found that
BCG/CWS could radiosensitise HCT-116 colorectal can-
cer cells via autophagy. Further investigation of the signal-
ling pathway showed the generation of ROS due to
up-regulation of JNK and ERK. Thus, the MAPK path-
way was involved in the autophagy process. The efficacy
of radiotherapy treatment of HCT-116 tumours in the
mouse model was found to be significantly improved
when combined with BCG/CWS [33]. Another study
done by Rouschop et al. (2010) [21] focussed on hypoxia
and the effect of autophagy in radiosensitivity. Their re-
sults showed that hypoxia could stimulate autophagy in
HCT-116 and HT-29 colorectal cell lines and decreased
radiosensitivities in vitro. Also, MAP1LC3B and Atg5
were found to be involved and regulated by the PERK-
arm of UPR. Inhibition of autophagy by adding CQ
caused the increase of radiosensitivity. Verification of ex-
perimental results was done in xenograft of HCT-116
tumour in mouse and the use of CQ in blocking autoph-
agy and increasing radiotherapy efficacy was validated
[21]. Although the two studies employed different strat-
egies in autophagy modulation for improving radiosensi-
tivity, both measures tried to perturb autophagy from
basal levels to improve treatment results.
Prostate cancer
Prostate cancer is a common cancer in men and is usu-
ally treated by radiotherapy and radical prostatectomy.
Although the current treatment has a high therapeutic
efficacy, relapses are common among high risk patients
and thus radiosensitisation is studied to improve treat-
ment effectiveness [34]. In a study comparing 54 biopsy
specimens of prostate cancer with normal prostate tis-
sue, it was found that prostate cancer cells had a higher
level of light chain 3A (LC3A) and lower level of
lysosome-associated membrane protein 2 (LAMP2a),
which are markers of autophagosome and lysosome cel-
lular content respectively. Moreover, the study used two
cell lines DU145 (radiosensitive) and PC3 (radioresis-
tant) to study the level of autophagy after irradiation.
Results showed that PC3 has a greater autophagic flux
after irradiation than DU145 with a higher level of LC3A
and a lower level of LAMP2a. Adding MG132 (blocker
of proteasome pathway) caused a decrease in LC3A and
an increase in p62 and LAMP2a, showing the halt of au-
tophagy and this radiosensitised both cell lines. There-
fore, this study concluded that a high level of autophagy
could compromise the treatment efficiency of radiother-
apy [34]. Another study investigated the use of mTOR
inhibitor RAD001 for radiosensitising prostate cancer
cell lines DU145 and PC3. Also, the additional use of Z-
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VAD, the inhibitor of caspase-dependent apoptosis, was
found to further enhance autophagy and the cytotoxic
effects of radiation. Finally, PTEN (common mutation of
the suppressor of PI3K-Akt pathway) deficient cell lines
could offer some further improvement of radiosensitisa-
tion. Thus, the promotion of autophagy by mTOR inhib-
ition may improve radiotherapy efficacy in prostate
cancer [35]. These two studies provided opposing views
on the promotion of autophagy to improve the radiosen-
sitivities of prostate cancer cells. The discrepancy could
be due to the different autophagy levels attained by dif-
ferent autophagy promoters. Thus, accurate quantifica-
tion of autophagy level should be developed for
understanding the influence of autophagy in prostate
cancer treatment.
Summary of autophagy modulation on improving
radiotherapy efficacy in different cancer types
The strategies used in the major studies on different
cancer types can be divided into three main categories.
The most common direction is the induction of autoph-
agy through promoting the PI3K-Akt-mTOR pathway,
mainly by using mTOR inhibitors. This strategy has
been adopted among glioblastoma, oral, lung, breast,
oesophageal and prostate cancers. The second direction
is the induction of autophagy through promoting the
MAPK pathway by inducing ER stress. This has been
employed in pancreatic, colorectal and prostate cancers.
The third category is the inhibition of autophagy
through the UPR pathway, which is achieved by the
addition of chloroquine as exemplified in the glioblast-
oma and colorectal cancer studies. All strategies are
aimed at adjusting the autophagy level of tumour cells
to improve treatment efficacy.
Future development
As summarised above, there were conflicting results re-
garding the effect of autophagy in radiosensitising tu-
mours for improving radiotherapy efficacy. Therefore,
more investigation is needed before implementing
modulation of autophagy in clinical settings [36]. There
are two aspects which have been identified for further
development. The first aspect is the establishment of au-
tophagy level for individual tumours. It is difficult as au-
tophagy is hard to quantify, for example, the number of
autophagosomes is not directly related to the level of au-
tophagy as an increased number of autophagosomes
could represent a reduced rate of turnover apart from an
increased rate, and a reduced number of autophago-
somes may represent an increase of autophagic flux [2].
Moreover, tissue biopsy experiments would have to be
performed for individual patients instead of relying on
established cancer cell line results because different
tumour samples may have varied basal autophagy levels
and tumour microenvironments. Also, personalised
treatments by modifications of tumour microenviron-
ment and treatment modalities schemes would need to
be investigated. In particular, hypoxia and the varied
radiotherapy dose scheme, and differences in autophagy
pathways between preclinical and clinical studies need
to be investigated as the cellular pathways have multiple
feedback loops and backup mechanisms. This way, the
full picture of autophagy mechanism may be obtained
and its relationship with current cancer treatment mo-
dalities such as radiotherapy may be used with higher
precision. The second aspect is the specialisation of au-
tophagy induction or inhibition drugs. Currently,
autophagy inducers or inhibitors used in preclinical
studies mostly have different primary usages, such as
CQ, which is a drug used for the treatment of malaria
[2]. These drugs have systemic effects and are not specif-
ically targeted at tumour cells. It is possible that the ra-
diosensitivity of normal tissue is also increased, leading
to an increase in radiation injuries [37]. Moreover, the
mTOR inhibitor rapamycin has been used in early clin-
ical trials and was found to cause proteinuria as podo-
cytes depend on the mTOR pathway to control
autophagic flux for proper functioning [38]. Therefore,
specialised autophagy induction or inhibition agents
with tumour specific uptake and accumulation are
needed to enable modification of autophagy and redu-
cing side effects at the clinical stage.
Conclusion
Autophagy, a vitally important cellular mechanism that
affects tumour survival and proliferation, provides a
valuable target for enhancing cancer treatment efficacy
apart from current modalities such as radiotherapy.
However, as autophagy is a two-edged sword that may
promote the destruction or protection oftumour cells,
based on the different tumour type and stage, and may
interact with current treatment modalities, resulting in
an improved or worsened prognosis. More extensive re-
search and development is needed to successfully modify
autophagy for clinical gains, especially for establishing a
quantified autophagy level with an individual tumour
microenvironment and treatment scheme consider-
ations, and the specialisation of autophagy agents for
overcoming the systemic effect of autophagy agents on
patients.
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